g can further accelerate this timeline. Once the RNA production platform is established, the overall clinical development process could, in principle, be further accelerated by the utilization of a computational model‐aided QbD platform, which would complement the platform production, independent of the RNA sequence. This would enable the development of a platform process agnostic to the infectious disease target, which can be rapidly deployed to both develop candidate vaccines for testing and large‐scale manufacture. Despite the numerous production and affordability advantages, the RNA platform still remains unproven with no commercial vaccine developed using this "disruptive" technology. As multiple organizations exploit this technology to develop vaccines against SARS‐CoV‐2, the benefits and practical limitations of this technology will be tested, providing lessons for further iteration and improvements.

This research is funded by the Department of Health and Social Care using UK Aid funding and is managed by the Engineering and Physical Sciences Research Council (EPSRC, Grant No. EP/R013764/1). The views expressed in this publication are those of the author(s) and not necessarily those of the Department of Health and Social Care.


1. Introduction {#sec1-micromachines-10-00838}
===============

Manufacturing technologies for material removal have been constantly evolving to fulfill consumer requirements. Currently, downscaling of processes such as machining, injection molding, and electric discharge machining (EDM) is needed to produce microscale workpieces that are used in fields ranging from aeronautical to biomedical applications \[[@B1-micromachines-10-00838],[@B2-micromachines-10-00838]\]. Despite the existence of several competing technologies, drilling is the most common and still in high demand. Frequently, the manufacturing of a through bore-hole is characterized by the formation of entrance and exit burrs. The dimension of the exit burr exceeds that of the entrance burr considerably. Owing 